Fujimycin also named Tacrolimus, is an immunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection. It achieves this by inhibiting calcineurin involved in the production of interleukin-2, a molecule that promotes the development and proliferation of T cells, which are vital to the body's learned (or adaptive) immune response.
This report contains market size and forecasts of Fujimycin in global, including the following market information:
Global Fujimycin Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Fujimycin Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Fujimycin companies in 2021 (%)
The global Fujimycin market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Capsule Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Fujimycin include Novartis, Mylan, Astellas Pharma, Pfizer, Accord Healthcare, Dr. Reddy Labs, Panacea Biotec, Jina Pharma and LEO Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Fujimycin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Fujimycin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Fujimycin Market Segment Percentages, by Type, 2021 (%)
Capsule
Ointment
Injection
Others
Global Fujimycin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Fujimycin Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Fujimycin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Fujimycin Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Fujimycin revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Fujimycin revenues share in global market, 2021 (%)
Key companies Fujimycin sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Fujimycin sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Mylan
Astellas Pharma
Pfizer
Accord Healthcare
Dr. Reddy Labs
Panacea Biotec
Jina Pharma
LEO Pharma
Glenmark Pharmaceutical
Veloxis
Strides Pharma
Hisun Pharmaceutical
Sinopharm Chuan Kang Pharmaceutical
Zhongmei Huadong Pharmaceutical